Researchers are exploring the use of chimeric antigen receptor macrophages to target fibroblast activation protein, with potential applications in treating various conditions, including liver and lung fibrosis, solid tumors, and cardiac fibrosis. The approach involves engineering macrophages to have anti-inflammatory and therapeutic effects. Studies are investigating different methods, such as in situ engineering and RNA therapeutics, to enhance the efficacy of these CAR-macrophages in various disease models.